| INTRODUCTION
Sickle cell disease (SCD) is an inherited, autosomal recessive, monogenic hemoglobinopathy. 1 Although this disease is caused by a single base pair mutation in the hemoglobin β-chain gene, persons with SCD can experience varying severity of a number of complications, including vaso-occlusive episodes that can result in acute chest syndrome (ACS), pain, stroke, chronic ischemic organ damage, disability, and early death. 2 SCD shows marked variability in disease severity.
The patho-physiology underline complications in SCD remains incompletely understood. This could be attributed to co-existing environmental, psychosocial, and genetic factors. However, such known causes of variation are still insufficient to fully explain the clinical heterogeneity of the disease. Accordingly, identification of genetic alterations that may modulate disease severity is of great interest. 3 Vasculopathy and endothelial dysfunction are the most important contributors to many long-term complications of SCD as cerebral strokes, renal dysfunction, and pulmonary hypertension. 4 Protein Z (PZ), a vitamin K-dependent glycoprotein synthesized in the liver. 5, 6 PZ level is mandatory for controlled inhibition of activated coagulation factor X (FXa), the key player of the common coagulation pathway. 7 PZ binds PZ protease inhibitor (ZPI), a member of the serpin-super family of protease inhibitors forming the PZ-ZPI complex which inhibits FXa on phospholipid surfaces in the presence of calcium. This in turn reduces the formation of prothrombinase complex, resulting in inhibition of thrombin generation. 6, 8 Single-nucleotide polymorphisms (SNPs) in Protein Z gene were reported to be associated with decreased PZ plasma level, thus affecting its anti-coagulant capacity and increasing the risk of thrombotic tendency as ischemic stroke, cardiovascular diseases, retinal vessel occlusion, pregnancy-related complications, and vaso-occlusive crises (VOC) in SCD patients.
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Endothelin-1 (ET-1) is one of the most potent endogenous vasoconstrictors known. It acts through type A (ETRA) and B (ETRB) receptors, leading to cell proliferation and vasoconstriction. 12 Endothelial dysfunction increases ET-1 production, leading to vascular hypertrophy, atherogenesis, and in the kidney, glomerulosclerosis.
13-15
Endothelin-1 (EDN1) gene polymorphism with G-to-T substitution at nucleotide 5665 in exon 5 (rs5370; corresponding to a Lys/Asn change at codon 198) was found to be associated with increased vascular reactivity, 16 hypertension in obese populations, 17 heart failure, 18 malignant arrhythmias in adults with structural cardiac disease, 19 preeclampsia 20 , and pulmonary artery hypertension.
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As previous studies in SCD reported that pro-thrombotic conditions associated with altered PZ and ET-1 levels may influence, at least in part, the susceptibility to vascular complications in sickle patients, the aim of the current study was to clarify the possible impact of co- 
| MATERIALS AND METHODS
The present study included 100 sickle cell disease patients who were attending Pediatric Hematology Clinic of El-Mounira Children
Hospital, Cairo University. They were 53 males and 47 females. Their ages ranged between 3 and 18 years. Hundred age-and sex-matched un-related healthy children with normal hemoglobin electrophoresis were included in the study as a control group. Informed consents were obtained from the parents or caregivers of participants in advance. 
| Genotyping of Protein Z (PROZ G79A; rs3024735) SNP
The 
What is Known
• Sickle cell disease (SCD) is a monogenic disease characterized by clinical variability.
• Vasculopathy is a major complication in SCD.
• Protein Z and Endothelin-1 genetic polymorphisms may increase the thrombotic risk.
What is New
• There was no significant difference noticed between pediatric SCD patients having the wild genotype or the polymorphic genotypes of Protein Z G79A
polymorphism.
• Endothelin-1 G5665T polymorphism could be considered as a molecular predictor for pulmonary dysfunction and severe VOC in SCD.
T A B L E 1 Clinical and laboratory data of SCD patients 
| Statistical analysis
Data were analyzed using SPSS (Statistical Package for the Social Science; SPSS Inc., Chicago, IL, USA) statistical package version 17.
For numerical data, parametric data were expressed as mean, standard deviation, and range, while nonparametric data were expressed as median and interquartile range. Qualitative data were expressed as frequency and percentage. Chi-square test or Fisher's exact test was used to examine the relation between qualitative variables.
Nonparametric numerical data were analyzed using Mann-Whitney test. Correlation analysis was performed by Spearman's rank correlation. Unconditional logistic regression analysis was used to calculate odds ratios (OR) and 95% confidence intervals (CI) for risk estimation.
P-values less than .05 were considered significant. Chi-square (v2) test was performed to assess deviation from Hardy-Weinberg equilibrium (HWE).
| RESULTS
The demographic data of SCD patients is presented in Table 1 . The frequency of Protein Z G79A and Endothelin-1 G5665T genotypes in SCD patients and controls is presented in Table 2 . Genotypic distribution of the studied SNPs in the studied population was in accordance with the Hardy-Weinberg equilibrium (P>.05). The distribution of Endothelin-1 (EDN1 G5665T) and Protein Z (PROZ G79A) polymorphic genotypes did not differ between SCD patients and controls.
Comparison between patients having the wild or the polymorphic genotypes of Protein Z (PROZ G79A) revealed no statistically significant difference between the two groups regarding their gender, clinical, or laboratory characteristics (Tables S1 and S2 ). Endothelin-1
G5665T polymorphic genotypes was associated with pulmonary dysfunction (pulmonary hypertension and acute chest syndrome) and severe frequent VOC (Tables S3 and S4 ).
| DISCUSSION
Sickle cell disease patients suffer from acute and chronic vascular complications. Vascular occlusion is a major pathophysiologic event in SCD, leading to a diverse group of morbidities such as painful crisis, acute chest syndrome, stroke, aseptic necrosis of bones, priapism, leg ulcers, and proliferative retinopathy. 23 The variable clinical spec- Regarding of Protein Z G79A polymorphism, 73% of SCD patients had the wild genotype (GG), 27% had the heteromutant genotype (GA), while none of the patients had the homomutant genotype (AA). These frequencies go with that previously reported in Bahraini patients being 65%, 29%, and 5% for the GG, GA, and AA genotypes, respectively.
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SCD complications may be modified by genetic and acquired risk factors for vasculopathy and several studies have reported that Proein Z G79A polymorphism is associated with thrombotic complications.
In the present work, patients harboring the polymorphic genotypes were compared to those with the wild genotype and there was no statistically significant difference between the two patients' groups regarding their clinical or laboratory features. Although the frequency and severity of VOC were higher in patients having the variant genotypes, the difference between the two patients' groups did not reach a statistically significant level. This could be attributed to the sample size of our study, or the unreported attacks of VOC missed by the patients or their caregivers. The study of Mahdi and colleagues 25 reported that the polymorphic genotypes were significantly higher in SCD patients with VOC, and this SNP could be considered as molecular risk factor for vaso-occlusion.
Endothelin-1 (EDN-1) gene polymorphisms have been investigated and incriminated in the pathogenesis of various vascular diseases. The mutant T allele of a G5665T polymorphism was found to be associated with higher plasma ET-1 levels. 16, [26] [27] [28] In our study, 64%
of SCD patients had the wild genotype (GG) of Endothelin-1 G5665T polymorphism, 20% had the heteromutant genotype (GT) and 7%
had the homomutant genotype (TT). These frequencies were close to that reported in African, African American, and in Indian SCD patients. 3, 11, 29 There was no statistical difference in the distribution of the polymorphic genotypes between SCD patients and controls. This goes with that previously reported in Indian and African population. 3, 29 However, the study of Navarro and colleagues 11 has found a statistically significant difference in the genotypic and allelic frequencies of END1 G5665T SNP between African American sickle patients and controls. The difference between the studied populations potentially reflects the role of ancestry.
Acute chest syndrome (ACS) and painful vaso-occlusive crises (VOC) are the most common causes of hospitalization in sickle cell disease. Several studies have suggested the involvement of Endothelin-1 in the pathogenesis of these two sickle cell anemia-specific complications. 30, 31 Furthermore, Endothelin-1 (rs5370) gene polymorphism has been implicated in progression of chronic glomerulosclerosis, 26 pulmonary hypertension 27 , and vaso-occlusive episodes correlated with pain history. 28 In our study, statistical comparison between patients having the wild and the polymorphic genotypes revealed that pulmonary dysfunction in the form of pulmonary hypertension and acute chest syndrome, and severe vaso-occlusive attacks requiring hospitalization were more frequent among patients harboring the polymorphic genotypes. On the contrary, the study of Thakur et al. 3 has shown that ET-1 G5665T SNP has no significance among native African SCD.
In the current study, the polymorphic genotypes were significantly higher among male patients. However, Thakur et al. 3 reported that the distribution of the polymorphic genotypes was not sex-linked.
In conclusion, Endothelin-1 (EDN1 G5665T) polymorphism could be considered as a molecular predictor for severe VOC and pulmonary complications in pediatric Egyptian SCD patients. Larger confirmatory studies and wide scale analysis are recommended to confirm our results, and further researches in this field are required to identify more genetic variants that could help in understanding the molecular mechanisms underlying the pathophysiology of the disease and to explain the clinical variability between SCD patients. 
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